These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 19596644)

  • 1. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes.
    Murphy CG; Seidman AD
    Clin Breast Cancer; 2009 Jun; 9 Suppl 2():S58-65. PubMed ID: 19596644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
    Rivera E
    Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
    Bhushan S; Walko CM
    Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Other options in the treatment of advanced breast cancer.
    Cobleigh MA
    Semin Oncol; 2011 Jun; 38 Suppl 2():S11-6. PubMed ID: 21600380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
    J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy for metastatic breast cancer].
    Schmid P; Possinger K
    Zentralbl Gynakol; 2006 Dec; 128(6):318-26. PubMed ID: 17213969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
    Tanabe M; Ito Y; Tokudome N; Sugihara T; Miura H; Takahashi S; Seto Y; Iwase T; Hatake K
    Breast Cancer; 2009; 16(4):301-6. PubMed ID: 19205831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone: clinical role in metastatic breast cancer.
    Denduluri N; Swain S
    Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer.
    Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y
    J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming taxane and anthracycline resistance.
    Zelnak A
    Breast J; 2010; 16(3):309-12. PubMed ID: 20408821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approved agents for metastatic breast cancer.
    Fornier MN
    Semin Oncol; 2011 Jun; 38 Suppl 2():S3-10. PubMed ID: 21600382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.